117P Three-year invasive disease-free survival results from a phase II study of pyrotinib plus trastuzumab and albumin-bound paclitaxel as neoadjuvant treatment in HER2-positive early or locally advanced breast cancerTing Luo, Deyou Zheng, Xiaoyan Zhong et al.|ESMO Open|2024Cited by 0